Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOBID vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP, and blocking adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity,Off-label: Adjuvant in treatment of obstructive sleep apnea
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
Theophylline extended-release capsules: 300-600 mg/day orally divided every 12 hours. Initial dose 300 mg/day, titrate based on serum concentrations (target 10-20 mcg/m L). Max 600 mg/day unless serum levels monitored.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Neonates: 24-36 h; Children (1-9 y): 3-4 h; Adults (non-smokers): 6-12 h; Adults (smokers): 4-5 h; Hepatic cirrhosis: prolonged (up to 30 h); Heart failure: prolonged (up to 20 h).
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Exhibits saturable (nonlinear) pharmacokinetics at high doses.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal (10% unchanged), hepatic metabolism (90%, primarily via CYP1A2 and CYP3A4); 20% excreted in feces as metabolites.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
40-60% (primarily to albumin). Decreased binding in neonates, hepatic disease, and uremia.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.45 L/kg (range: 0.3-0.7 L/kg). Higher in neonates (0.7-0.9 L/kg). Represents distribution throughout total body water.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral: 96-100% (immediate release); Sustained release (THEOBID): ~100% (bioequivalent to immediate release at steady state); IV: 100%; Rectal: ~80-100%.
Oral: 40-50%; Inhalation: 20-30%
No specific GFR-based dose adjustment for theophylline. However, accumulation may occur in severe renal impairment; monitor serum levels and adjust dose to achieve therapeutic concentrations (10-20 mcg/m L).
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh Class A: Reduce dose by 50%. Child-Pugh Class B or C: Reduce dose by 75% or use alternative. Monitor serum concentrations closely.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
For asthma: Oral immediate-release: 5 mg/kg/day divided q6-8h. Extended-release: 10-20 mg/kg/day divided q12h (max 600 mg/day). Target serum concentration 5-15 mcg/m L. Dosing based on age and weight, titrate slowly.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Elderly patients (>60 years) often have reduced clearance. Start with 300 mg/day orally extended-release, titrate slowly to lowest effective dose. Monitor serum concentrations closely to avoid toxicity (target 5-15 mcg/m L).
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No FDA black box warning.
No FDA black box warning.
Risk of serious cardiovascular toxicity (arrhythmias, seizures, death) especially at serum levels >20 mcg/m L,Cautious use in patients with peptic ulcer, seizure disorders, cardiac disease, hepatic impairment,Monitor serum theophylline levels to avoid toxicity,Reduce dose in smokers and with drugs that induce CYP1A2 (e.g., phenytoin, rifampin),Avoid in patients with active peptic ulcer or uncontrolled seizure disorders
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline or any component of the formulation,Active peptic ulcer disease,Uncontrolled seizure disorders
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
High-fat meals can increase absorption of sustained-release formulations. Charcoal-broiled foods and a high-protein, low-carbohydrate diet can increase theophylline clearance. Avoid concurrent ingestion of caffeine-containing foods/beverages.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Theophylline (THEOBID) is not considered a major teratogen. First trimester: Limited data show no significant increase in congenital malformations. Second and third trimesters: No known structural effects; fetal tachycardia and irritability may occur due to maternal toxicity. Neonatal withdrawal (jitteriness, vomiting) reported with third-trimester use.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels may reach therapeutic concentrations, especially in preterm neonates. Risk of irritability, jitteriness, and feeding problems. Benefit of breastfeeding should be weighed against potential adverse effects; monitor infant for theophylline toxicity.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Pregnancy increases theophylline clearance due to elevated cardiac output and increased hepatic metabolism, particularly in the second and third trimesters. Dose may need to be increased by 30-50% to maintain therapeutic levels. Postpartum, clearance decreases; dose should be reduced to prepregnancy levels within 2 weeks to avoid toxicity. Monitor serum levels and adjust accordingly.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Theophylline levels must be monitored; narrow therapeutic index (5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders. Use with caution in heart failure, hepatic impairment, and elderly. Many drug interactions (e.g., cimetidine, fluoroquinolones, macrolides) increase levels. Smoking induces metabolism, requiring higher doses.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take exactly as prescribed; do not change dose without consulting doctor.,Do not crush or chew sustained-release capsules.,Avoid excessive caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms like nausea, vomiting, palpitations, insomnia, or seizures.,Notify doctor if you start or stop smoking, or if you are prescribed new medications.,Keep regular appointments for blood level monitoring.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOBID vs AEROLATE III, answered by our medical review team.
THEOBID is a Bronchodilator that works by Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP, and blocking adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOBID and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOBID is: Theophylline extended-release capsules: 300-600 mg/day orally divided every 12 hours. Initial dose 300 mg/day, titrate based on serum concentrations (target 10-20 mcg/m L). Max 600 mg/day unless serum levels monitored.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOBID and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOBID is classified as Category C. Theophylline (THEOBID) is not considered a major teratogen. First trimester: Limited data show no significant increase in congenital malformations. Second and third trimesters: No . AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.